-
Views
-
Cite
Cite
Ian R Hardy, Nadia Anceriz, François Rousseau, Matt B Seefeldt, Eric Hatterer, Magali Irla, Vanessa Buatois, Laurence E Chatel, Andrew Getahun, Ashley Fletcher, Laura Cons, Guillemette Pontini, Nicole A Hertzberg, Giovanni Magistrelli, Pauline Malinge, Mia J Smith, Walter Reith, Marie H Kosco-Vilbois, Walter G Ferlin, John C Cambier, Anti-CD79 Antibody Induces B Cell Anergy That Protects against Autoimmunity, The Journal of Immunology, Volume 192, Issue 4, February 2014, Pages 1641–1650, https://doi.org/10.4049/jimmunol.1302672
Close - Share Icon Share
Abstract
B cells play a major role in the pathogenesis of many autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and type I diabetes mellitus, as indicated by the efficacy of B cell–targeted therapies in these diseases. Therapeutic effects of the most commonly used B cell–targeted therapy, anti-CD20 mAb, are contingent upon long-term depletion of peripheral B cells. In this article, we describe an alternative approach involving the targeting of CD79, the transducer subunit of the B cell AgR. Unlike anti-CD20 mAbs, the protective effects of CD79-targeted mAbs do not require cell depletion; rather, they act by inducing an anergic-like state. Thus, we describe a novel B cell–targeted approach predicated on the induction of B cell anergy.
